| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_948d4720640a28f2c5061fda7a6f9c78 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-892 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate |
2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9547c78a415a8616f73b8bb440fad482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f485488dea3e630b2dbbf4f76bb4c39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4260b35a9e79299eb9601a786491a847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb4b97b3f60fb497a68b50eed9a9e7a7 |
| publicationDate |
2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202144403-A |
| titleOfInvention |
A high-affinity TCR that recognizes HPV16 |
| abstract |
The present invention provides a T cell receptor (TCR), which has the property of binding YMLDLQPET-HLA A0201 complex; and the binding affinity of the TCR to the YMLDLQPET-HLA A0201 complex is the same as that of wild-type TCR to YMLDLQPET-HLA A0201 At least 2 times the binding affinity of the complex. The invention also provides fusion molecules of such TCRs with therapeutic agents. Such TCRs can be used alone or in combination with therapeutic agents to target YMLDLQPET-HLA A0201 complex tumor cells. |
| priorityDate |
2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |